Previous 10 | Next 10 |
Image source: The Motley Fool. Incyte Corp (NASDAQ: INCY) Q2 2020 Earnings Call Aug 4, 2020 , 8:00 a.m. ET Operator Continue reading
Incyte Corporation (INCY) Q2 2020 Earnings Conference Call August 04, 2020 08:00 AM ET Company Participants Mike Booth - Head of Investor Relations Hervé Hoppenot - Chairman, President & Chief Executive Officer Barry Flannelly - Executive Vice President, General Manager,...
The following slide deck was published by Incyte Corporation in conjunction with their 2020 Q2 earnings Read more ...
Incyte ( INCY ) Q2 results : More news on: Incyte Corporation, Healthcare stocks news, Earnings news and commentary, , Read more ...
Incyte (NASDAQ: INCY ) : Q2 Non-GAAP EPS of $1.24 beats by $0.37 ; GAAP EPS of $1.32 beats by $0.65 . More news on: Incyte Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
Total product and royalty revenues of $593 million (+16% vs Q2 2019) for the quarter ended June 30, 2020; Jakafi ® (ruxolitinib) revenues of $474 million in Q2 2020 (+16% vs Q2 2019) Monjuvi ® (tafasitamab-cxix; collaboration with MorphoSys) approved by U.S. FDA; launc...
Incyte (NASDAQ: INCY ) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. The consensus EPS Estimate is $0.87 (+16.0% Y/Y) and the consensus Revenue Estimate is $614.07M (+15.9% Y/Y). Over the last 2 years, INCY has beaten EPS estimates 75% of th...
The FDA approval of MorphoSys' Monjuvi, in a treatment in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), has triggered a $25 million milestone payment and royalty on net sales for Xencor (NASDAQ: XNCR ) , the co. announce...
Morphosys AG (NASDAQ: MOR ) and collaboration partner/licensee Incyte (NASDAQ: INCY ) announce the FDA nod for Monjuvi (tafasitamab-cxix), combined with lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specif...
- First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need - FDA granted Monjuvi Fast Track, Breakthrough Therapy and Priority Review designations - MorphoSys and Incyte will co-commercialize Monju...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...